Ang-2 has been identified as a natural antagonist of Ang-1, and it is able to inhibit Ang-1-mediated Tie-2 phosphorylation, thus interfering with angiogenesis.
Primary antibodies against Ang-1, Ang-2, Tie-2, and [beta]-actin, as well as secondary antibodies against either rabbit or mouse IgG were purchased from Santa Cruz Biotechnology, Inc.
RNA (2 mg) was then reverse-transcribed into cDNA using the SuperScriptTM III First-Strand Synthesis System RT-PCR kit and was further amplified using SYBR Green RT-PCR with the following specific oligonucleotides: Ang-1 sense primer, 5'-CAG CAC AAA GGA CGC TGA TA-3' and antisense primer, 5'-ATA GCG CCT TCA GAA GTC CA3'; Ang-2 sense primer, 5'-GAT CTT GTC TTG GCC TCA GC-3' and antisense primer, 5'-ACG GCG TTA GAC ATG TAG GG-3'; Tie-2 sense primer, 5'-AGG GCC TAG AGC CAG AGA CT-3' and antisense primer, 5'-AAG GTC TTT AGG GGC TGG AA-3'; or [beta]-actin sense primer, 5'-CAC CCG CGA GTA CAA CCT TC-3' and antisense primer, 5'-CCC ATA CCC ACC ATC ACA CC-3'.
Materials and Methods: Ang-2 and Tie-2 were measured in plasma samples from AML patients and controls using enzyme-linked immunosorbent assay (ELISA).
Yontem ve Gerecler: AMLli hastalar ve kontorllerden alinan plazma orneklerinde, Enzim bagli immunassay (ELISA) ile Ang-2 ve Tie -2 olculmustur.
sonuc: Calismada elde edilen sonuclarda, AML hastalarinin dolasimdaki Ang-2 ve sTie-2 duzeylerinin prognostik anlamliligi gosterilmistir.
In cerebral malaria, the research showed ANG-1 and ANG-2 were deregulated, likely contributing to excessive activation of the endothelial cells and parasite obstruction of brain blood vessels, associated with cerebral malaria.
High levels of ANG-2 and low levels of ANG-1 were associated with the severity of disease; the levels recorded on admission to hospital predicted which children would subsequently die.
Pharmaceutical compositions which comprise a therapeutically effective amount of Ang-2
protein and/or a vector comprising a nucleic acid molecule that comprises the nucleotide coding sequence of Ang-2
and methods of using such compositions to treat individuals suspected of having cancer are disclosed.
Samples of the maternal caruncular (CAR) and fetal cotyledonary (COT) portions of the placenta were snap frozen and later analyzed for vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor- 1 (VEGFR-1), vascular endothelial growth factor receptor-2 (VEGFR-2), angiopoietin-1 (ANG-1), angiopoietin-2 (ANG-2
), receptor for both Ang-1 and Ang-2
Tie-2, fibroblast growth factor (FGF), endothelial nitric oxide synthase (eNOS), and soluble guanylate cyclase (sGC).
06) in ANG-2
expression over the DETA control treatments.
To evaluate placental expression of some major angiogenic factors, CAR and COT from the same ewes were snap frozen and VEGF, VEGFR-1, VEGFR-2, ANG-1, ANG-2
and Tie-2 mRNA concentrations were measured by real-time RT-PCR (ABI Prism 7000[R]).